Yahoo
Shanghai - Delayed Quote CNY

Nanjing Vazyme Biotech Co., Ltd (688105.SS)

22.58 +0.66 (+3.01%)
At close: October 30 at 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 688105.SS
  • Previous Close 21.92
  • Open 21.65
  • Bid 22.57 x --
  • Ask 22.58 x --
  • Day's Range 20.92 - 24.51
  • 52 Week Range 12.89 - 29.16
  • Volume 17,139,654
  • Avg. Volume 14,722,358
  • Market Cap (intraday) 11.674B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.01
  • Earnings Date --
  • Forward Dividend & Yield 0.50 (2.21%)
  • Ex-Dividend Date Jun 3, 2026
  • 1y Target Est 21.30

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. It serves research institutions, high-throughput sequencing service providers, molecular diagnostic reagent manufacturers, pharmaceutical companies, vaccine companies, contract research organizations (CROs), hospitals, and medical institutions. The company was founded in 2012 and is headquartered in Nanjing, China.

www.vazyme.com

3,002

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688105.SS
51.88%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

688105.SS
32.43%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

688105.SS
3.95%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

688105.SS
60.33%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY23
Revenue 298.26M
Earnings 4.7M
Profit Margin 1.58%

Q1

FY23

Q2

FY23

Q3

FY23

0
100M
200M
0.0%
0.5%
1.0%
1.5%

Analyst Insights

View More

Analyst Price Targets

19.59 Low
21.30 Average
22.58 Current
23.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.06%

  • Return on Assets (ttm)

    -0.88%

  • Return on Equity (ttm)

    -0.26%

  • Revenue (ttm)

    1.56B

  • Net Income Avi to Common (ttm)

    993.15k

  • Diluted EPS (ttm)

    -0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.79B

  • Total Debt/Equity (mrq)

    23.54%

  • Levered Free Cash Flow (ttm)

    276.43M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: